ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.924,19
-1,12%
S&P 500
5.035,69
-1,57%
US Dollar vs BRL
5,1959
0,01%
Bitcoin
56.956,79
-6,01%
Brent Oil
85,275
-0,72%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) Notícias

AIM AIM ImmunoTech Inc

0,4085
0,00 (0,00%)
Pré-mercado
Última atualização: 05:00:00
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
AIM ImmunoTech Inc AIM AMEX Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,00 0,00% 0,4085 05:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
0,4085
mais cotações »

Notícias Recentes

Data Hora Fonte Título
29/04/202409:55GLOBEAIM ImmunoTech Announces First Dose Level is Generally..
25/04/202409:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
18/04/202409:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/04/202409:55GLOBEAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting..
11/04/202412:00GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
10/04/202409:21GLOBEAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned..
02/04/202408:30GLOBEAIM ImmunoTech Reports Fourth Quarter and Full Year 2023..
28/03/202409:05GLOBEAIM ImmunoTech to Present at the MedInvest Biotech & Pharma..
26/03/202410:05GLOBEAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023..
25/03/202410:05GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
22/03/202409:55GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
20/03/202410:25GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/03/202409:45GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
07/03/202410:45GLOBEAIM ImmunoTech Announces Launch of CEO Corner Platform
29/02/202410:45GLOBEAIM ImmunoTech Outlines Recent Progress Across Clinical..
14/02/202410:55GLOBEAIM ImmunoTech Announces First Subject Dosed in the..
08/02/202410:50GLOBEAIM ImmunoTech Reports Positive Topline Results from Phase 2..
24/01/202411:10GLOBEAIM ImmunoTech Receives Erasmus Medical Center Ethics Board..
22/01/202410:55GLOBEAIM ImmunoTech Announces that the First Subject is Enrolled..
10/01/202410:45GLOBEAIM ImmunoTech Announces Open Enrollment for Phase 1b/2..
05/01/202415:32BWAIM Shareholders Elect All Four Company Director Nominees at..
03/01/202418:05PRNUSKellner Seeking Expedited Appeal of Delaware Court Finding..
29/12/202310:00BWDelaware Court Rules in Favor of AIM ImmunoTech and Upholds..
28/11/202318:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
27/11/202311:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
21/11/202314:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
15/11/202309:30GLOBEAIM ImmunoTech Reports Third Quarter 2023 Financial Results..
14/11/202312:00GLOBEAIM ImmunoTech Announces Publication of Data from Roswell..
09/11/202310:05GLOBEAIM ImmunoTech to Discuss Third Quarter 2023 Financial..
08/11/202310:45GLOBEAIM ImmunoTech Announces Encouraging Translational Data from..
06/11/202311:25BWAIM ImmunoTech Files Definitive Proxy Statement and Sends..
30/10/202309:55GLOBEAIM ImmunoTech Announces Abstract Accepted for Poster..
17/10/202309:45GLOBEAIM ImmunoTech Engages Business Development Firm, Azenova,..
22/09/202310:05GLOBEAIM ImmunoTech Selected to Present at the 3rd Annual Marie..
11/09/202314:00GLOBEAIM ImmunoTech Announces Report of Complete Topline Data..
05/09/202310:05GLOBEAIM ImmunoTech to Present at the H.C. Wainwright 25th Annual..
23/08/202309:00BWAIM ImmunoTech Rejects Director Nomination Notice from..
15/08/202307:45GLOBEAIM ImmunoTech Reports Second Quarter Financial Results and..
09/08/202310:05GLOBEAIM ImmunoTech to Discuss Second Quarter 2023 Financial..
08/08/202309:05GLOBEAIM ImmunoTech Announces Completion of Enrollment in Phase 2..
18/07/202320:30GLOBEAIM ImmunoTech Issues Notice that an Unaffiliated Third..
10/07/202309:05GLOBEAIM ImmunoTech Enrolls and Doses First Subject in Phase 2..
05/07/202309:35GLOBEAIM ImmunoTech to Participate in the Virtual Investor Summer..
27/06/202312:16GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
27/06/202309:45GLOBEAIM ImmunoTech Announces Authorizations from Competent..
14/06/202309:45GLOBEAIM ImmunoTech to Participate in the Healthcare Virtual..
12/06/202309:45GLOBEAIM ImmunoTech Outlines Recent Significant Progress Across..
07/06/202320:11PRNCAAIMIA ADOPTS SHAREHOLDER RIGHTS PLAN TO PROTECT AGAINST..
15/05/202309:45GLOBEAIM ImmunoTech Reports First Quarter Financial Results and..
09/05/202309:50GLOBEAIM ImmunoTech to Discuss First Quarter 2023 Financial..

Seu Histórico Recente

AMEX
AIM
AIM ImmunoTech
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados